IL278935B2 - Piazolo[e-3,4]pyrimidine compounds are being modified for use in cancer treatment - Google Patents

Piazolo[e-3,4]pyrimidine compounds are being modified for use in cancer treatment

Info

Publication number
IL278935B2
IL278935B2 IL278935A IL27893520A IL278935B2 IL 278935 B2 IL278935 B2 IL 278935B2 IL 278935 A IL278935 A IL 278935A IL 27893520 A IL27893520 A IL 27893520A IL 278935 B2 IL278935 B2 IL 278935B2
Authority
IL
Israel
Prior art keywords
pde1
pde1 inhibitor
cells
substituted
alkyl
Prior art date
Application number
IL278935A
Other languages
English (en)
Hebrew (he)
Other versions
IL278935B1 (en
IL278935A (en
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of IL278935A publication Critical patent/IL278935A/en
Publication of IL278935B1 publication Critical patent/IL278935B1/en
Publication of IL278935B2 publication Critical patent/IL278935B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL278935A 2018-05-25 2019-05-24 Piazolo[e-3,4]pyrimidine compounds are being modified for use in cancer treatment IL278935B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862676638P 2018-05-25 2018-05-25
US201862688641P 2018-06-22 2018-06-22
PCT/US2019/033941 WO2019227004A1 (en) 2018-05-25 2019-05-24 Organic compounds

Publications (3)

Publication Number Publication Date
IL278935A IL278935A (en) 2021-01-31
IL278935B1 IL278935B1 (en) 2025-12-01
IL278935B2 true IL278935B2 (en) 2026-04-01

Family

ID=68616034

Family Applications (2)

Application Number Title Priority Date Filing Date
IL278935A IL278935B2 (en) 2018-05-25 2019-05-24 Piazolo[e-3,4]pyrimidine compounds are being modified for use in cancer treatment
IL322048A IL322048A (en) 2018-05-25 2019-05-24 Organic compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL322048A IL322048A (en) 2018-05-25 2019-05-24 Organic compounds

Country Status (11)

Country Link
US (1) US12636287B2 (enExample)
EP (2) EP3802545A4 (enExample)
JP (1) JP7493460B2 (enExample)
KR (1) KR20210013214A (enExample)
CN (1) CN112189013A (enExample)
AU (1) AU2019275453B2 (enExample)
BR (1) BR112020024037A2 (enExample)
CA (1) CA3099283A1 (enExample)
IL (2) IL278935B2 (enExample)
MX (1) MX2020012628A (enExample)
WO (1) WO2019227004A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
MX2024010993A (es) * 2022-03-11 2024-09-17 Intra Cellular Therapies Inc Compuestos organicos.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690935A (en) * 1983-03-31 1987-09-01 Wayne State University Inhibition of tumor growth and metastasis with calcium channel blocker compounds
US20140235556A1 (en) * 2011-09-27 2014-08-21 Biomed Valley Discoveries, Inc. Compositions and methods of treating gliomas
WO2016044667A1 (en) * 2014-09-17 2016-03-24 Intra-Cellular Therapies, Inc. Compounds and methods
WO2018093591A1 (en) * 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7783679B2 (en) 2005-01-12 2010-08-24 Computer Associates Think, Inc. Efficient processing of time series data
WO2006133261A2 (en) 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
AU2007256633B2 (en) 2006-06-06 2013-09-12 Intra-Cellular Therapies, Inc. Organic compounds
EP2939676A1 (en) 2007-12-06 2015-11-04 Intra-Cellular Therapies, Inc. Organic compounds
ES2588238T3 (es) 2007-12-06 2016-10-31 Intra-Cellular Therapies, Inc. Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
AU2009322899A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
MX2011005934A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
AU2009322903A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
PE20110922A1 (es) 2008-12-06 2012-01-22 Intra Cellular Therapies Inc DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1)
EA201170769A1 (ru) 2008-12-06 2012-02-28 Интра-Селлулар Терапиз, Инк. Органические соединения
BRPI0922700A2 (pt) 2008-12-06 2015-08-11 Intracellular Therapies Inc Compostos orgânicos
US8993572B2 (en) 2010-04-22 2015-03-31 Intra-Cellular Therapies, Inc. Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US9371327B2 (en) 2010-05-31 2016-06-21 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
EP2575817A4 (en) 2010-05-31 2014-01-08 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2012177263A1 (en) 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
WO2013138118A1 (en) 2012-03-14 2013-09-19 The Regents Of The University Of California Treatment of inflammatory disorders in non-human mammals
US9499562B2 (en) 2012-06-18 2016-11-22 Dart Neuroscience (Cayman) Ltd. Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds
AR091507A1 (es) 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
DK2970279T3 (da) 2013-03-15 2020-11-30 Intra Cellular Therapies Inc Organiske forbindelser
ES2717688T3 (es) * 2013-03-15 2019-06-24 Intra Cellular Therapies Inc Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP
WO2014169087A2 (en) 2013-04-10 2014-10-16 The Trustees Of Columbia University In The City Of New York Treatment of proximal spinal muscular atrophy
TW201609713A (zh) 2013-12-19 2016-03-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
TW201611834A (en) 2014-02-07 2016-04-01 Lundbeck & Co As H Hexahydrofuropyrroles as PDE1 inhibitors
EA032579B1 (ru) 2014-04-04 2019-06-28 Х. Лундбекк А/С Галогенированные хиназолин-тгф-амины в качестве ингибиторов pde1
DK3157926T3 (da) 2014-06-20 2019-08-19 Intra Cellular Therapies Inc Organiske forbindelser
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
US10849862B2 (en) 2014-12-26 2020-12-01 Theravalues Corporation Formulation of curcumin and anti-PD-1 antibody
TW201643167A (zh) 2015-04-22 2016-12-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之咪唑並三酮
EP3288980B1 (en) 2015-04-28 2021-03-10 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
US11291666B2 (en) 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
CN110574502B (zh) 2016-09-12 2023-04-18 麦斯卓微电子(南京)有限公司 Mems致动系统和方法
EP4112053B1 (en) 2016-10-11 2024-02-14 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Treatment of synucleinopathies
US10633382B2 (en) 2016-10-18 2020-04-28 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
CA3047579A1 (en) 2016-12-22 2018-06-28 Abbvie Inc. Compositions and methods of enhancing or augmenting type i ifn production
AU2018325445A1 (en) 2017-08-31 2020-03-19 Abbvie Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1) inhibitors and uses thereof
EP3856191A4 (en) 2018-09-25 2022-06-22 Intra-Cellular Therapies, Inc. NOVEL USES
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
US12599603B2 (en) 2019-09-03 2026-04-14 Intra-Cellular Therapies, Inc. Methods of treatment
MX2024010993A (es) 2022-03-11 2024-09-17 Intra Cellular Therapies Inc Compuestos organicos.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690935A (en) * 1983-03-31 1987-09-01 Wayne State University Inhibition of tumor growth and metastasis with calcium channel blocker compounds
US20140235556A1 (en) * 2011-09-27 2014-08-21 Biomed Valley Discoveries, Inc. Compositions and methods of treating gliomas
WO2016044667A1 (en) * 2014-09-17 2016-03-24 Intra-Cellular Therapies, Inc. Compounds and methods
WO2018093591A1 (en) * 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROWTHER FB., ET AL., CYCLIC NUCLEOTIDE PHOSPHODIESTERASE?1C (PDE1C) DRIVES CELL PROLIFERATION, MIGRATION AND INVASION IN GLIOBLASTOMA MULTIFORME CELLS IN VITRO, 25 January 2015 (2015-01-25) *

Also Published As

Publication number Publication date
EP3802545A1 (en) 2021-04-14
EP4520399A2 (en) 2025-03-12
MX2020012628A (es) 2021-01-29
CN112189013A (zh) 2021-01-05
AU2019275453B2 (en) 2023-12-21
US20210205310A1 (en) 2021-07-08
IL278935B1 (en) 2025-12-01
JP7493460B2 (ja) 2024-05-31
BR112020024037A2 (pt) 2021-02-09
CA3099283A1 (en) 2019-11-28
US12636287B2 (en) 2026-05-26
EP4520399A3 (en) 2025-03-26
IL278935A (en) 2021-01-31
JP2021525705A (ja) 2021-09-27
WO2019227004A1 (en) 2019-11-28
EP3802545A4 (en) 2022-03-16
AU2019275453A1 (en) 2020-12-03
IL322048A (en) 2025-09-01
KR20210013214A (ko) 2021-02-03

Similar Documents

Publication Publication Date Title
IL266170A (en) A process for the preparation of pyrazolo[1,5-a]pyrimidines and their salts
ZA201804972B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
IL270909A (en) Imidazo[1,2-a]pyrazine modulators of the adenosine a2a receptor
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
PL3762385T3 (pl) Podstawione 1,2-dihydro-3h-pirazolo[3,4-d]pirymidyn-3-ony
SG10201807952PA (en) Jak1 inhibitors for the treatment of myelodysplastic syndromes
SMT201900266T1 (it) Composti di pirazolo[1,5-a]piramidin-5,7-diammina come inibitori di cdk e loro uso terapeutico
EP3215509A4 (en) Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
IL282740B2 (en) 4-Tetrahydropyran-4-yl-6-fluoro-7-phenyl-8,7,6,5-tetrahydro-H1-pyrido[3,2-d]pyrimidine-2,4-dione
IL262673A (en) A pyrazolo[5,1-a]pyrimidine compound
ZA202100259B (en) Pyrrolo[1,2-b]pyridazine derivatives
EP3215510A4 (en) Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
IL290419B (en) Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
IL267801A (en) Process for the preparation of 3-disubstituted 5-amino-h6-thiazolo[5,4-d]pyrimidine-7,2-dione compounds
IL272988A (en) Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors
HUE056561T2 (hu) Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
HUE047822T2 (hu) Immun- vagy gyulladásos betegségek és rák kezelésére alkalmas 7-(morfolin-4-il)pirazol[1,5-a]pirimidin-származékok
IL253427B (en) The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose
HK40031579A (en) Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
HK1238643A1 (en) Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis
GB201613403D0 (en) Pyrrolo[2,3-d]pyrimidin-4-amine compounds and their use in treating cancer